Results 281 to 290 of about 107,800 (308)

Mesothelioma

Disease-a-Month, 2011
Gregory, Fuhrer, Angeline A, Lazarus
openaire   +2 more sources

Immunotherapy approaches for malignant pleural mesothelioma

Nature Reviews Clinical Oncology, 2022
Dean A Fennell
exaly  

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly  

Mesothelioma

2006
Joseph R. Testa, Michele Carbone
openaire   +1 more source

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Nature Medicine, 2021
Patrick Forde, Valsamo Anagnostou, Suzanne E Dahlberg   +2 more
exaly  

Mesothelioma and Asbestosis

Respiration, 1968
E.A. Gaensler, R Belleau
openaire   +3 more sources

Mesothelioma

Medical Journal of Australia, 1984
openaire   +2 more sources

Mesothelioma

2008
Stahel, R, Felley-Bosco, E, Opitz, I, Weder, W   +3 more
openaire   +1 more source

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Lancet Oncology, The, 2021
Dean A Fennell, Christian Hermann Ottensmeier, Joanne Lord   +2 more
exaly  

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Ca-A Cancer Journal for Clinicians, 2019
Michele Carbone, Prasad S Adusumilli, Paul Baas   +2 more
exaly